moomoo
Open in the moomoo APP.
OPEN
Pfizer reports strong Q4 earnings with the FY23 guidance
25K Views ·6 Posts
Pfizer Inc. (PFE) on Tuesday reported its latest earnings results. The Earnings Highlights are below:
▶️ Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth.
▶️ Strong fourth-quarter 2022 revenues of $24.3 billion, reflecting 13% operational growth.
▶️ Full-year 2022 reported diluted EPS of $5.47, up 42% year-over-year, and adjusted diluted eps of $6.58, up 62% year-over-year, both of which represent all-time highs for Pfizer.
▶️ Fourth-quarter 2022 reported diluted EPS of $0.87, up 48% year-over-year, and adjusted diluted EPS of $1.14, up 45% year-over-year.
▶️ Provides full-year 2023 revenue guidance of $67.0 to $71.0 billion and adjusted diluted EPS guidance of $3.25 to $3.45.
1. Do you feel satisfied with the latest earnings results?
2. What's your opinion or analysis about the company?
▶️ Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth.
▶️ Strong fourth-quarter 2022 revenues of $24.3 billion, reflecting 13% operational growth.
▶️ Full-year 2022 reported diluted EPS of $5.47, up 42% year-over-year, and adjusted diluted eps of $6.58, up 62% year-over-year, both of which represent all-time highs for Pfizer.
▶️ Fourth-quarter 2022 reported diluted EPS of $0.87, up 48% year-over-year, and adjusted diluted EPS of $1.14, up 45% year-over-year.
▶️ Provides full-year 2023 revenue guidance of $67.0 to $71.0 billion and adjusted diluted EPS guidance of $3.25 to $3.45.
1. Do you feel satisfied with the latest earnings results?
2. What's your opinion or analysis about the company?
Pfizer Inc. (PFE) on Tuesday reported its latest earnings results. The Earnings Highlights are below:
▶️ Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth.
▶️ Strong fourth-quarter 2022 revenues of $24.3 billion, reflecting 13% operational growth.
▶️ Full-year 2022 reported diluted EPS of $5.47, up 42% year-over-year, and adjusted diluted eps of $6.58, up 62% year-over-year, both of which represent all-time highs for Pfizer.
▶️ Fourth-quarter 2022 reported diluted EPS of $0.87, up 48% year-over-year, and adjusted diluted EPS of $1.14, up 45% year-over-year.
▶️ Provides full-year 2023 revenue guidance of $67.0 to $71.0 billion and adjusted diluted EPS guidance of $3.25 to $3.45.
1. Do you feel satisfied with the latest earnings results?
2. What's your opinion or analysis about the company?
▶️ Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth.
▶️ Strong fourth-quarter 2022 revenues of $24.3 billion, reflecting 13% operational growth.
▶️ Full-year 2022 reported diluted EPS of $5.47, up 42% year-over-year, and adjusted diluted eps of $6.58, up 62% year-over-year, both of which represent all-time highs for Pfizer.
▶️ Fourth-quarter 2022 reported diluted EPS of $0.87, up 48% year-over-year, and adjusted diluted EPS of $1.14, up 45% year-over-year.
▶️ Provides full-year 2023 revenue guidance of $67.0 to $71.0 billion and adjusted diluted EPS guidance of $3.25 to $3.45.
1. Do you feel satisfied with the latest earnings results?
2. What's your opinion or analysis about the company?
Related Stocks
Pfizer
PFE
+0.52%
Moderna
MRNA
+0.98%
BioNTech
BNTX
-0.92%
New
Hot
ColumnPfizer stock dips on Q4 revenue miss, FY23 outlook sees COVID products decline
Welcome to click to follow~~
$Pfizer(PFE.US$ is trading lower premarket on Tuesday after mixed Q4 results and a full year 2023 outlook which is seen lower than expected.
Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating estimates while revenue increased +2% to $24.29B but missed analysts expectations.
COVID vaccine, developed with partner $BioNTech(BNTX.US$, Comirnaty direct sales and alliance revenues declined -9% Y/...
$Pfizer(PFE.US$ is trading lower premarket on Tuesday after mixed Q4 results and a full year 2023 outlook which is seen lower than expected.
Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating estimates while revenue increased +2% to $24.29B but missed analysts expectations.
COVID vaccine, developed with partner $BioNTech(BNTX.US$, Comirnaty direct sales and alliance revenues declined -9% Y/...
2
Pfizer (PFE) Earnings - Gloomy Road Ahead
Pfizer (PFE) just announced their Q4’2022 EPS of $1.14, beating the analysts’ estimate of $1.07. They booked a revenue of $100.3 bil for FY2022 thanks to the Covid vaccine and antiviral sales which contributed more than half of it. However, the fun ends here because they are forecasting up to a 33% decline in their revenue for FY2023 as the Covid pandemic eases and hence the plunge of the demand for its vaccine.
In an attempt to diversify from the Covid b...
In an attempt to diversify from the Covid b...
4
2
PFE Earnings
- Q4 Non-GAAP EPS of $1.14 beats by $0.10.
- Revenue of $24.3B (+1.9% Y/Y) misses by $100M.
2023 Guidance:
- Rev of $67.0 to $71.0 Billion vs. $74.23B consensus
- Adjusted Diluted EPS of $3.25 to $3.45 vs $4.38 consensus
Revenues from COVID-19 products expected to grow in 2024 after reaching a low point in 2023 due to significant government supply on hand to start the year.
- Revenue of $24.3B (+1.9% Y/Y) misses by $100M.
2023 Guidance:
- Rev of $67.0 to $71.0 Billion vs. $74.23B consensus
- Adjusted Diluted EPS of $3.25 to $3.45 vs $4.38 consensus
Revenues from COVID-19 products expected to grow in 2024 after reaching a low point in 2023 due to significant government supply on hand to start the year.
2
2
Post